The beat and raised guidance for all three key brands signal accelerating innovative portfolio momentum, but the 2% total revenue decline and 39% U.S. generic revenue drop highlight ongoing headwinds from lenalidomide erosion. Monitor WELTRUZA launch trajectory and biosimilars revenue exceeding $0.8B in 2026 for confirmation of the Pivot to Growth strategy.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 3 $41.91entry
- T+1 · yesterday −0.14%α −1.79% · $41.85
- T+2 · todayOpen
- T+5 · in 5d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva reported Q3 2026 non-GAAP diluted EPS of $0.86, beating the $0.72 consensus by 19.4%, while revenue of $4.395B came in above the $4.23B estimate. The beat was driven by strong innovative brand growth (AUSTEDO +21%, AJOVY +61%, UZEDY +96% YoY) and record non-GAAP gross margin of 58.7%, though total revenue declined 2% YoY due to generic erosion from lenalidomide competition. Teva raised its 2026 revenue outlook for all three key brands and increased its non-GAAP operating income guidance, offset by higher acquired IPR&D charges.
Key Financial Metrics
Key Facts
- Non-GAAP diluted EPS of $0.86 vs consensus $0.72, a beat of 19.4%
- Revenue of $4.395B vs consensus $4.23B, above estimates
- Total revenue declined 2% YoY to $4.395B, driven by 39% drop in U.S. generic product revenues due to lenalidomide competition
- Non-GAAP gross margin reached 58.7%, the highest quarterly level in the last decade (excluding Q4 2025 milestone payments)
- Key innovative brands (AUSTEDO, AJOVY, UZEDY) collectively grew 33% YoY to ~$1.1B
- AUSTEDO revenue raised to $2.55B-$2.65B (from $2.45B-$2.60B), AJOVY to $930M-$960M (from $850M-$870M), UZEDY to $290M-$310M (from $270M-$290M)
- Full-year 2026 non-GAAP diluted EPS guidance raised to $1.92-$2.11 (from $1.91-$2.11), non-GAAP operating income guidance raised to $3.8-$3.9B
- Free cash flow of $495M in Q3, full-year FCF guidance raised to $2.1-$2.4B
- FDA approval of WELTRUZA (olanzapine LAI) in October 2026 for schizophrenia; peak sales potential of $1.5B-$2.0B for LAI portfolio
- Acquired BXCL-501 from BioXcel Therapeutics; FDA action expected for at-home agitation treatment
- Returned to investment grade; refinanced ~$4.9B in debt during Q3
- GAAP diluted EPS of $0.20 declined 47% YoY due to higher impairments, legal charges, and debt extinguishment loss
Financial Impact
Non-GAAP EPS beat of $0.14 (19.4%) on $165M revenue beat; innovative brand revenue guidance raised by $100M-$150M each; full-year non-GAAP operating income guidance raised by $0.05B before $0.1B IPR&D charge
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| United States | $1.9B | -11.0% |
| Europe | $1.3B | +7.0% |
| International Markets | $592.0M | +6.0% |
Risk Factors
- Total revenue declined 2% YoY; generic erosion from lenalidomide competition may continue
- GAAP EPS fell 47% YoY due to $228M impairment charges, $202M legal settlements, and $224M debt extinguishment loss
- Higher R&D and S&M spending (+16% and +8% YoY) could pressure margins if revenue growth slows
- Full-year guidance includes $0.87B in acquired IPR&D charges, creating uncertainty around future deal costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394057 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 5, 2026 today | 144 | $41.89 | awaiting T+20 | awaiting T+20 | $41.78 (−0.26%) |
Nov 4, 2026 1d ago | 144 | $41.85 | awaiting T+20 | awaiting T+20 | $41.78 (−0.17%) |
Nov 3, 2026 2d ago | 8-K | No price | awaiting T+20 | awaiting T+20 | No price |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 3, 2026 2d ago | Press Release | $41.91 | awaiting T+20 | awaiting T+20 | $41.78 (−0.31%) |
Nov 2, 2026 3d ago | Press Release | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (−2.65%) |
Nov 2, 2026 3d ago | SC 13G/A | $40.70 | awaiting T+20 | awaiting T+20 | $41.78 (+2.65%) |
Oct 29, 2026 7d ago | 8-K | $42.09 | awaiting T+20 | awaiting T+20 | $41.78 (−0.74%) |
Oct 27, 2026 9d ago | Press Release | $40.39 | awaiting T+20 | awaiting T+20 | $41.78 (+3.44%) |
Oct 15, 2026 21d ago | Institutional Cluster | $41.11 | awaiting T+20 | awaiting T+20 | $41.78 (−1.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers